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Abstract
 
Dendritic cells (DCs) play a crucial role in the immune responses against infections by sensing
microbial invasion through toll-like receptors (TLRs). In humans, two distinct DC subsets,
CD11c
 
 
 
 plasmacytoid DCs (PDCs) and CD11c
 
 
 
 myeloid DCs (MDCs), have been identified
and can respond to different TLR ligands, depending on the differential expression of cognate
TLRs. In this study, we have examined the effect of TLR-7 ligands on human DC subsets.
Both subsets expressed TLR-7 and could respond to TLR-7 ligands, which enhanced the sur-
vival of the subsets and upregulated the surface expression of costimulatory molecules such as
CD40, CD80, and CD86. However, the cytokine induction pattern was distinct in that PDCs
and MDCs produced interferon (IFN)-
 
 
 
 and interleukin (IL)-12, respectively. In response to
TLR-7 ligands, the Th1 cell supporting ability of both DC subsets was enhanced, depending
on the cytokines the respective subsets produced. This study demonstrates that TLR-7 exerts
its biological effect in a DC subset-specific manner.
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Introduction
 
Dendritic cells (DCs) sense the presence of invading patho-
gens, engulf the pathogens, and degrade them intracellu-
larly. The function of DCs is not primarily to destroy
pathogens, but to prime naive T cells as professional APCs,
thereby linking innate and adaptive immunity (1, 2). How-
ever, it remains unknown how DCs regulate the quality of
T cell responses. Th cell development is mainly regulated
by DC-derived cytokines, such as IL-12 or IFN-
 
 
 
/
 
 
 
 (2,
3). Therefore, it is important to clarify how cytokine pro-
duction is regulated in the DCs. Recent progress in DC bi-
ology has suggested that cytokine production depends ei-
ther on DC subsets (lineage model) or on stimuli that DCs
receive (instruction model) (4).
Toll-like receptors (TLRs) are type I transmembrane
proteins that are expressed on APCs including macrophages
and DCs, and respond to pathogen-associated molecular
patterns (PAMPs) (5–9). After pathogen recognition, TLR
signaling can activate APCs to induce inflammatory cyto-
kines and upregulation of costimulatory molecules (7–14).
Expression of TLR family members (TLR-1–10) was in-
vestigated on two human blood DC subsets (12–14),
CD11c
 
 
 
 plasmacytoid DCs (PDCs) and CD11c
 
 
 
 myeloid
DCs (MDCs). Each subset expresses a different repertoire
of TLRs. For example, MDCs and PDCs express TLR-4
and TLR-9, respectively (13, 14). In accordance with their
TLR expression, they can respond to the respective TLR
ligands, LPS, or CpG DNA (12–14). These studies suggest
that cytokine production is determined by TLR expression
on DCs.
 
It has recently been demonstrated that imidazoquinoline
compounds, imiquimod, and its derivative, R-848, are
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specific ligands for TLR-7 (15). TLR-7 ligands, imidazo-
quinoline compounds, have potent antiviral and antitumor
properties in animals (16–19). In fact, imiquimod has been
clinically approved for the treatment of genital warts
caused by human papillomavirus (20). In this study, we in-
vestigate the biological effects of TLR-7 ligands on human
blood DC subsets, and show that (i) TLR-7 ligands are ca-
pable of affecting both PDCs and MDCs to enhance their
survival and to upregulate costimulatory molecules, and
that (ii) TLR-7 signaling selectively facilitates IFN-
 
 
 
 pro-
duction from PDCs and IL-12 production from MDCs,
resulting in induction of Th1 balance. These results suggest
that the cytokine induction pattern in response to TLR-7
ligands is determined not only by TLR-7 expression but
also by cell lineage.
 
Materials and Methods
 
Media and Reagents.
 
RPMI 1640 supplemented with 2 mM
 
L
 
-glutamine, 100 U/ml penicillin, 100 ng/ml streptomycin, and
heat-inactivated 10% FCS (Irvine Scientific) was used for the cell
culture throughout the experiments. Imiquimod (R-837) and
R-848 were synthesized in Pharmaceuticals and Biotechnology
Laboratory, Japan Energy Corporation (Saitama, Japan). CpG-
oligodeoxynucleotides (ODNs), phosphorothioate form: 2006
(TCGTCGTTTTGTCGTTTTGTCGTT) and phosphodiester
form: AAC-30 (ACCGATAACGTTGCCGGTGACGGCAC-
CACG) were purchased from Hokkaido System Science. ODN
2006 and AAC-30 were used at concentrations of 10
 
 
 
6
 
 M and
5
 
   
 
10
 
 
 
6
 
 M, respectively. LPS (
 
Salmonella typhimurium
 
) (1 
 
 
 
g/ml)
was purchased from Sigma-Aldrich. UV-irradiated Sendai virus
(SV) (HVJ: Cantell strain, provided by Sumitomo Pharmaceuti-
cals was used at 5 hemagglutinating U/ml. Recombinant human
cytokines, GM-CSF (used at a concentration of 100 ng/ml) and
IL-3 (at 10 ng/ml) were purchased from PeproTech EC.
 
Isolation of Blood DC Subsets.
 
Peripheral blood DC subsets
(MDCs and PDCs) were isolated according to the modified pro-
tocol, as described previously (21, 22). Briefly, the DC-enriched
population (CD4
 
 
 
/CD3
 
 
 
/CD14
 
 
 
 cells) was obtained from
PBMCs by negative and subsequent positive immunoselections.
The CD11c
 
 
 
/lineage
 
 
 
/DR
 
 
 
 cells (MDCs) and CD11c
 
 
 
/lineage
 
 
 
/
DR
 
 
 
 cells (PDCs) were sorted by an EPICS ALTRA
 
®
 
 flow cy-
tometer (Beckman Coulter) by using PE-labeled anti-CD11c
(Leu-M5; Becton Dickinson), mixture of FITC-labeled mAbs
against lineage markers, CD3 (M2AB; Exalpha), CD14 (FWKW-1;
Exalpha), CD15 (Leu-M1; Becton Dickinson), CD16 (J5511;
Exalpha), CD19 (SJ25C1; Becton Dickinson), and CD56
(NCAM16.2; Becton Dickinson), and allophycocyanin (APC)-
labeled HLA-DR (Tü36; Becton Dickinson). Blood CD14
 
 
 
CD16
 
  
 
monocytes were purified from PBMCs stained with
PE-labeled anti-CD16 (J5511) and FITC-labeled CD14
(FWKW-1) by cell sorting. The purity of each group of cells was
 
 
 
98%.
 
Analyses of Cultured DCs.
 
The sorted blood DC subsets or
PBMCs were cultured in 96-well, round-bottomed tissue culture
plates at 3
 
 
 
10
 
4
 
 cells in 200 
 
 
 
l of medium per well for 24 h. In
the viability assay, viable cells were evaluated as annexin V-nega-
tive fractions using annexin V-FITC Apoptosis Detection kit
(Genzyme) after cell debris was excluded by an appropriate for-
ward scatter threshold. To analyze the expression of costimula-
tory molecules, the culture cells were stained with FITC-labeled
 
anti-CD40 (5C3; BD PharMingen), CD86 (2331; BD PharMin-
gen), or CD80 (BB-1; Ancell) and analyzed by a FACScan™
(Becton Dickinson). The production of cytokines in the culture
supernatants was determined by ELISA 24 h later (kits for IL-12
p40
 
 
 
p70 and IFN-
 
 
 
 were purchased from Endogen).
 
DC–T Cell Coculture.
 
CD4
 
 
 
/CD45RA
 
 
 
 naive T cells were
obtained from allogeneic healthy volunteers using CD4
 
 
 
 T cell
Isolation kit (GmbH; Miltenyi Biotec) followed by positive selec-
tion with CD45RA-conjugated microbeads (Miltenyi Biotec).
The purity of the cells was 95% or greater by reanalysis. MDC
and PDC preincubated with GM-CSF, IL-3, or R-848 (10
 
 
 
6
 
 M)
for 24 h were washed and then cocultured with allogeneic
CD4
 
 
 
/CD45RA
 
 
 
 naive T cells (10
 
5
 
 cells per well, DC–T ratio,
1:5) for 7 d in 96-well, round-bottomed tissue culture plates. In
some experiments, neutralizing goat polyclonal anti–human IL-
12 Ab (AB-219-NA: 20 
 
 
 
g/ml) (R&D Systems) or a mixture of
neutralizing rabbit polyclonal anti–human IFN-
 
 
 
 Ab (2,000 neu-
tralization U/ml), neutralizing rabbit polyclonal anti–human
IFN-
 
 
 
 Ab (1,000 neutralization U/ml), and mouse anti–human
IFN-
 
 
 
/
 
 
 
 receptor mAb (20 
 
 
 
g/ml) (PBL Biomedical Laborato-
ries) was added into the coculture.
 
Intracellular Cytokine Staining.
 
Intracellular cytokine staining
in MDCs and PDCs was performed after 5 h R-848 (10
 
 
 
6
 
 M)
stimulation. 10 
 
 
 
g/ml brefeldin A (Sigma-Aldrich) was added
during the last 1 h. After the stimulation, MDCs and PDCs were
stained with Cy-Chrome-labeled CD40 (5C3; BD PharMingen),
and then fixed, permeabilized (FIX and PERM kit; Caltag Labo-
ratories), and stained with FITC-labeled anti–IL-12 p40
 
 
 
p70
mAb (B-P24; DIACLONE Research) or unconjugated mouse
anti–human IFN-
 
 
 
 mAb (MC-16; Genzyme). FITC-labeled
goat anti–mouse IgG F(ab
 
 
 
)
 
2
 
 (Becton Dickinson) was used as the
secondary antibody for anti–IFN-
 
 
 
 mAb after repermeabiliza-
tion. For detection of intracellular T cell cytokines, T cells after
the 7 d coculture were restimulated with PMA (50 ng/ml) and
ionomycin (2 
 
 
 
g/ml) for 6 h, and brefeldin A (10 
 
 
 
g/ml) was
added during the last 2 h (all from Sigma-Aldrich). The cells were
stained with phycoerythrin-cyanin 5.1 (PC5)-labeled anti-CD4
(ImmunoTech), and then with PE-labeled anti–IL-4 (Becton
Dickinson) plus FITC-labeled anti–IFN-
 
 
 
 mAb (Becton Dickin-
son) using FIX and PERM kit.
 
RT-PCR for TLRs.
 
Total RNA was prepared from sorted
MDCs, PDCs, and CD14
 
 
 
CD16
 
 
 
 blood monocytes using
TRIsol reagent (GIBCO BRL). RT reactions were performed
on 2 
 
 
 
g of total RNA using an oligo dT primer with SuperScript
II (GIBCO BRL). 1 
 
 
 
l aliquots of the DNA resulting from each
RT reaction were then subjected to PCR. The temperature pro-
files of PCR were as follows: an initial denaturation step of 94
 
 
 
C
for 5 min, followed by 35 cycles of 94
 
 
 
C for 30 s, 55
 
 
 
C for 30 s,
72
 
 
 
C for 1 min, and a final elongation step of 72
 
 
 
C for 7 min.
For detection of TLR mRNA, a primer set each of TLR4 and
TLR9 and three primer sets of TLR-7, as described previously
(12–14), were used. The sequences of primers were as follows:
TLR-4, forward: 5
 
 
 
-TTTCTGCAATGGATCAAGGACCA-3
 
 
 
,
reverse: 5
 
 
 
-GGACACCACAACAATCACCTTTC-3
 
 
 
; TLR-9,
forward: 5
 
 
 
-TTATGGACTTCCTGCTGGAGGTGC-3
 
 
 
, reverse:
5
 
 
 
-CTGCGTTTTGTCGAAGACCA-3
 
 
 
; the first set of TLR-7
(13), forward: 5
 
 
 
-TCTACCTGGGCCAAAACTGTT-3
 
 
 
, re-
verse: 5
 
 
 
-GGCACATGCTGAAGAGAGTTA-3
 
 
 
; the second set
of TLR-7 (12), forward: 5
 
 
 
-AGTGTCTAAAGAACCTGG-3
 
 
 
,
reverse: 5
 
 
 
-CTTGGCCTTACAGAAATG-3
 
 
 
; the third set of
TLR-7 (14), forward: 5
 
 
 
-CGAACCTCACCCTCACCATTA-
3
 
 
 
, reverse: 5
 
 
 
-GGGACGGCTGTGACATTGTTA-3
 
 
 
; and
 
 
 
-actin, forward: 5
 
 
 
-GACCCAGATCATGTTTGAGACCT- 
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TCAACAC-3
 
 
 
, reverse: 5
 
 
 
-TACTTGCGCTCAGGAGGAG-
CAATGATCTTG-3
 
 
 
. A 
 
 
 
X174 DNA-HaeIII Digest (New
England BioLabs) was used as a DNA size marker.
 
Results
 
Expression of TLR-7 in DCs.
 
First, we analyzed the ex-
pression of TLR-7 in MDCs and PDCs using the RT-PCR
method (Fig. 1). Krug et al. (13), but not Jorossay et al.(14),
observed TLR-7 expression in MDCs. Kadowaki et al. de-
tected weak, but significant expression of TLR-7 in MDCs
through real-time PCR (12). Taking this discrepancy into
consideration, we investigated TLR-7 expression with the
three different sets of PCR primers employed in these stud-
ies. TLR-7 mRNA was shown to be unequivocally ex-
pressed in both MDCs and PDCs (Fig. 1 and data not
shown). On the other hand, MDCs and PDCs reciprocally
expressed TLR-4 and TLR-9; MDCs expressed TLR-4 but
not TLR-9, while PDCs expressed TLR-9 but not TLR-4.
 
Effects of TLR-7 Ligands on Survival and Expression of Co-
stimulatory Molecules on DCs.
 
We next examined the bio-
logical effects of TLR-7 ligands, imiquimod and its deriva-
tive, R-848 (15), on MDCs and PDCs. Isolated MDCs and
PDCs were incubated with various agents for 24 h and
were then analyzed for cell viability and the expression of
costimulatory molecules. As shown in Fig. 2, both DC
 
subsets, especially PDCs, mostly died within 24 h in the
absence of stimuli. GM-CSF prevented MDCs from dying,
while IL-3 or CpG-ODNs (phosphorothioate form [2006]
and phosphodiester form [AAC30]) efficiently blocked the
cell death of PDCs, a result that was consistent with the
previous studies (11, 13, 22). TLR-7 ligands were shown
to enhance the survival of both MDCs and PDCs. The sur-
vival-promoting effect of R-848 was 
 
 
 
100-fold more po-
tent than that of imiquimod, which is consistent with their
effects on murine cells (15).
Furthermore, TLR-7 ligands could upregulate the sur-
face expression of the costimulatory molecules, CD40,
CD80 and CD86 on both MDCs and PDCs (Fig. 3). Their
expression levels were comparable between the two DC
subsets. As previously demonstrated, CpG-ODNs (2006 or
AAC30) could enhance surface expression of these costim-
ulatory molecules on PDCs but not on MDCs (11, 13).
The effects of TLR-7 ligands on PDCs were equivalent to
those of CpG-ODN (2006). Collectively, these results sug-
gest that TLR-7 signaling can enhance survival rates and
costimulatory molecule expression on PDCs and MDCs at
comparable levels.
 
Effects of TLR-7 Ligands on Cytokine Production of DCs.
Serum levels of IL-12 and IFN-  were elevated when mice
were intraperitoneally injected with the TLR-7 ligands
(15). Therefore, we next examined the effect of TLR-7
ligands on cytokine production from DCs, especially focus-
ing on IL-12 and IFN- . LPS and Sendai virus (SV) differ-
entially activated MDCs and PDCs to produce large
amounts of IL-12 p40 p70 (total IL-12) (Fig. 4 A) and
IFN-  (Fig. 4 B), respectively.
Both imiquimod and R-848 definitely induced total IL-
12 production from MDCs in a dose–dependent manner
(Fig. 4 A). However, these compounds as well as the other
stimuli tested were much less effective or had no effect on
IL-12 production from PDCs. By contrast, TLR-7 ligands
were demonstrated to be potent stimulators of IFN-  pro-
duction of PDCs (Fig. 4 B). The effects were manifested in
a dose–dependent manner and were even more potent than
those of the CpG-ODNs tested. However, the TLR-7
ligands had no capacity to induce IFN-  production from
MDCs. Titration analysis again demonstrated that the effect
of the imidazoquinolines on cytokine induction (IL-12
from MDCs and IFN-  from PDCs) was  100-fold stron-
ger in R-848 than in imiquimod.
Figure 1. mRNA expression of TLRs in MDCs and PDCs. mRNA
expression of TLR-4, -7, and -9 was examined in purified blood MDCs,
PDCs, and CD14 CD16  monocytes by RT-PCR. For the detection of
TLR-7 mRNA, three sets of primers were used, and similar results were
obtained when using each set. The results using the first set of TLR-7
primers (as described in Materials and Methods) are shown in the figure.
The data shown are representative of two independent experiments.
Figure 2. TLR-7 ligands enhance the sur-
vival of both MDCs and PDCs. MDCs and
PDCs were incubated for 24 h with various
stimuli. The viable cells in each DC subset
were evaluated as annexin V-negative frac-
tions by flow cytometry. The results are rep-
resentative of three independent experiments.1510 TLR-7 Ligands Differentially Activate DC Subsets
Intracellular cytokine staining also showed that R-848
induced the synthesis of IL-12 and IFN-  in MDCs and
PDCs, respectively (Fig. 4 C). Both IL-12–producing
MDCs and IFN- –producing PDCs exclusively expressed
CD40, indicating that DCs maturated by TLR-7 ligands
produce cytokines.
Effects of TLR-7 Ligands on DC-mediated Th Polarization.
To elucidate how TLR-7 ligands affect the DC-mediated
T cell responses, MDCs and PDCs were preincubated with
R-848 for 24 h, and then cocultured with allogeneic naive
CD4  T cells. As shown in Fig. 5, GM-CSF–treated
MDCs preferentially induced Th1 development, while IL-
3–treated PDCs facilitated Th2 skewing, in agreement with
the previous reports (22–24). TLR-7 ligand-stimulated
MDCs more strongly induced Th1 development than
GM-CSF–treated MDCs, and this effect was markedly
blocked by the addition of anti–IL-12 Ab (IL-12  Ab), but
not by the addition of a mixture of anti–IFN-  Ab, anti–
Figure 3. TLR-7 ligands upregu-
late the expression of costimulatory
molecules on both MDCs and
PDCs. After 24-h culture with vari-
ous stimuli, the expression levels of
CD40, CD80, and CD86 on each
DC subset were analyzed by flow
cytometry. Imiquimod and R-848
were used at concentrations of 10 5 M
and 10 7 M, respectively. The re-
sults are shown as  MFI, which is
calculated by subtraction of MFI
with the isotype-matched control
from that with each mAb. The re-
sults shown here are representative
of three independent experiments.
Figure 4. TLR-7 ligands induce the production of IL-12 and IFN-  from MDCs and PDCs, respectively. (A and B) After 24-h culture with various
stimuli, concentration of IL-12 p40 p70 (A) and IFN-  (B) in the culture supernatants of MDCs, PDCs, and PBMCs were measured by ELISA. The
data are shown by means   SEM of five independent experiments. (C) After 5-h culture with R-848 (10 6 M), intracellular staining of IL-12 and IFN- 
in MDCs and PDCs, together with the staining of surface expression of CD40, was performed. Percentages of the respective cytokine producing DCs are
indicated. This figure represents the results from one of three experiments.1511 Ito et al. Brief Definitive Report
IFN-  Ab, and anti–IFN- /  R Ab (IFN- s Abs). TLR-7
ligand-stimulated PDCs also developed IFN- –producing
cells. This Th1 induction was substantially inhibited by the
addition of IFN- s Abs, but not by the addition of IL-12 
Ab. Thus, both PDCs and MDCs can augment their Th1
cell supporting ability in response to TLR-7 ligands
through distinct cytokines.
Discussion
It remains a key issue whether DC response is deter-
mined by cell lineage or by stimuli. TLRs on DCs are ma-
jor receptors for various pathogenic stimuli. Therefore, it is
quite important to evaluate how DCs are activated by TLR
signaling. Of the TLRs, TLR-2, -4, and -9 are expressed in
either MDCs or PDCs (12–14). In accordance with the ex-
pression of TLR-2, -4, and -9, each DC subset differen-
tially responds to respective TLR ligands. MDCs can se-
crete IL-12 through TLR-2 or TLR-4 signaling (12–14),
whereas PDCs can produce IFN- /  through TLR-9 sig-
naling (11–14, 25, 26). Thus, human DCs can produce
subset-specific cytokines in response to PAMPs. These
findings favor the idea that the DC lineage is critical for es-
tablishing DC response. However, TLRs for these PAMPs
are differentially expressed in the DC subsets (12–14, and
Fig. 1). Therefore, it cannot formally be concluded
whether the microbial response is determined by TLR ex-
pression or DC lineage.
Unlike TLR-4 and -9, TLR-7 was constitutively ex-
pressed on both PDCs and MDCs (Fig. 1). In this context,
TLR-7 ligands should be useful tools to clarify how the
same pattern recognition stimuli lead to activation of dis-
tinct DC subsets. Consistent with the TLR-7 expression,
the ligands, imiquimod and R-848, enhanced the survival
of both PDCs and MDCs (Fig. 2) and induced their phe-
notypical maturation (Fig. 3). In contrast, TLR-7 ligands
showed differential cytokine-inducing effects on different
DC subsets; IFN-  from PDCs (Fig. 4 B) versus IL-12
from MDCs (Fig. 4 A). These results indicate that the
TLR-7–induced cytokine induction pattern is determined
not only by TLR expression but also by DC lineage. In
other words, DC lineage as well as instructive stimuli are
decisive factors affecting DC response, at least in the TLR-7
system.
At present, it remains unknown why TLR-7 exerts dif-
ferential outcomes in distinct DC subsets. In response to
TLR-4 ligand, cytokine induction depends on MyD88,
whereas DC maturation can proceed without MyD88, in-
dicating that MyD88 is a bifurcation point in TLR-4 sig-
naling (27). However, all effects of TLR-7 signaling de-
pend on MyD88 (15). Therefore, it is likely there is
another bifurcation point leading to the expression of
IFN-  or IL-12.
In determining Th responses, the DC system shows not
only lineage heterogeneity, but also functional plasticity
depending on the signals or environmental instruction (2,
4, 22–24, 28). In the microbial environment, MDCs ac-
quire Th1-inducing activity in response to TLR-2 or
TLR-4 ligands (12–14). Meanwhile, PDCs can also sup-
port Th1 cell development in response to a TLR-9 ligand,
CpG DNA (25, 26). These immunogenic Th1 responses
are mediated by IL-12 and IFN- /   from MDCs and
PDCs, respectively (22, 29). In line with this paradigm of
Th1 responses, this study shows that TLR-7 signaling af-
fects both DC subsets so that they support the differentia-
tion of naive Th cells also toward Th1 cells, depending on
the cytokines each DC subset secretes (Fig. 5). Thus, DC
subsets are programmed to make different innate responses
in terms of cytokine production, but can both eventually
cause the same Th1 induction.
In conclusion, TLR-7 ligands, imiquimod and its deriva-
tive, had discernible immunostimulatory effects on both
human PDCs and MDCs. In addition, our results uncov-
ered a possible new member of TLRs that has the potential
to evoke IFN-  production from PDCs. Remarkably, the
TLR-7–dependent cytokine production pattern is deter-
mined by the lineage commitment of the DC subsets.
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Figure 5. MDCs and PDCs stimulated by TLR-7
ligands induce Th1 development depending on each
DC-derived cytokine. MDCs and PDCs were preincu-
bated with the cytokines or R-848 (10 6 M) for 24 h,
washed, and subsequently cocultured with allogeneic
CD4  naive T cells for 7 d in the presence or absence
with neutralizing anti-IL-12 Ab (IL-12  Ab) or a mix-
ture of neutralizing anti–IFN-  Ab, neutralizing anti–
IFN-  Ab, and anti-IFN- /  R mAb (IFN- s Abs).
Intracellular cytokine profiles in the T cells were ana-
lyzed by flow cytometry. Percentages of the respective
cytokine-producing T cells are indicated. This figure
represents the results from one of three experiments.1512 TLR-7 Ligands Differentially Activate DC Subsets
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